Papanicolau-Sengos et al. [135] has demonstrated over-expression of CD122, CD155 and CD276 (B7-H3) that differentiated HRPC from HSPC, representing another potential target for aggressive PCa immunotherapy. The gene discussed is CD276; the disease is posterior cortical atrophy.